Personalized therapy in endometrial cancer: Challenges and opportunities

Shannon N. Westin, Russell R. Broaddus

Risultato della ricerca: Contributo su rivistaArticolo di reviewpeer review

Abstract

Early stage endometrial cancer is generally curable. However, progress in the treatment of advanced and recurrent endometrial cancer has been limited. This has led to a shift from the use of traditional chemotherapeutic agents and radiotherapy regimens to the promising area of targeted therapy, given the large number of druggable molecular alterations found in endometrial cancer. To maximize the effects of directed targeted therapy, careful molecular characterization of the endometrial tumor is necessary. This represents an important difference in the use of targeted therapy vs. traditional chemotherapy or radiation treatment. This review will discuss relevant pathways to target in endometrial cancer as well as the challenges that arise during development of a personalized oncology approach.

Lingua originaleInglese
pagine (da-a)1-13
Numero di pagine13
RivistaCancer Biology and Therapy
Volume13
Numero di pubblicazione1
DOI
Stato di pubblicazionePubblicato - 1 gen 2012
Pubblicato esternamente

Fingerprint

Entra nei temi di ricerca di 'Personalized therapy in endometrial cancer: Challenges and opportunities'. Insieme formano una fingerprint unica.

Cita questo